These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

593 related items for PubMed ID: 30027399

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
    Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, Nissinen H, Leinonen M, Stocchi F, Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) Investigators.
    Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson's disease.
    Jeong SH, Chung SJ, Yoo HS, Hong N, Jung JH, Baik K, Lee YH, Sohn YH, Lee PH.
    Brain; 2021 May 07; 144(4):1127-1137. PubMed ID: 33895825
    [Abstract] [Full Text] [Related]

  • 5. Low-dose levodopa therapy in Japanese patients with Parkinson's disease: a retrospective study.
    Kitagawa M, Tashiro K.
    Intern Med; 2005 Sep 07; 44(9):939-43. PubMed ID: 16258207
    [Abstract] [Full Text] [Related]

  • 6. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, PKDS009 Study Group.
    CNS Drugs; 2004 Sep 07; 18(11):733-46. PubMed ID: 15330687
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
    Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE.
    N Engl J Med; 2000 May 18; 342(20):1484-91. PubMed ID: 10816186
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
    de la Fuente-Fernández R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, Ruth TJ, Stoessl AJ.
    Brain; 2004 Dec 18; 127(Pt 12):2747-54. PubMed ID: 15329355
    [Abstract] [Full Text] [Related]

  • 14. Effect of Subthalamic Deep Brain Stimulation on Levodopa-Induced Dyskinesia in Parkinson's Disease.
    Kim JH, Chang WS, Jung HH, Chang JW.
    Yonsei Med J; 2015 Sep 18; 56(5):1316-21. PubMed ID: 26256974
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Levodopa-induced dyskinesia in Parkinson's disease: still no proof? A meta-analysis.
    Giannakis A, Chondrogiorgi M, Tsironis C, Tatsioni A, Konitsiotis S.
    J Neural Transm (Vienna); 2018 Sep 18; 125(9):1341-1349. PubMed ID: 29352351
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.